SG11202108867VA - Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia - Google Patents
Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemiaInfo
- Publication number
- SG11202108867VA SG11202108867VA SG11202108867VA SG11202108867VA SG11202108867VA SG 11202108867V A SG11202108867V A SG 11202108867VA SG 11202108867V A SG11202108867V A SG 11202108867VA SG 11202108867V A SG11202108867V A SG 11202108867VA SG 11202108867V A SG11202108867V A SG 11202108867VA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- myeloid leukemia
- acute myeloid
- treating acute
- flt3 inhibitor
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 title 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title 1
- 229940075628 hypomethylating agent Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190021228 | 2019-02-22 | ||
| KR1020200021502A KR20200102949A (en) | 2019-02-22 | 2020-02-21 | A pharmaceutical composition comprising FLT3 inhibitor and Hypomethylating agent for the treatment of the acute myeloid leukemia |
| PCT/KR2020/002536 WO2020171646A1 (en) | 2019-02-22 | 2020-02-21 | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108867VA true SG11202108867VA (en) | 2021-09-29 |
Family
ID=72470030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108867VA SG11202108867VA (en) | 2019-02-22 | 2020-02-21 | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3928780A4 (en) |
| KR (1) | KR20200102949A (en) |
| CN (1) | CN113490497A (en) |
| AU (1) | AU2020226111A1 (en) |
| CA (1) | CA3130244A1 (en) |
| EA (1) | EA202191984A1 (en) |
| IL (1) | IL285628A (en) |
| SG (1) | SG11202108867VA (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210002015A (en) * | 2019-06-27 | 2021-01-06 | 한미약품 주식회사 | A pharmaceutical composition comprising FLT3 inhibitor and chemotherapeutic agents for the treatment of the acute myeloid leukemia |
| WO2023287797A2 (en) * | 2021-07-12 | 2023-01-19 | Quteba Ebrahem | A method of treating cancer or a blood disorder |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2670498A1 (en) | 2006-11-28 | 2008-06-05 | Novartis Ag | Combination of iap inhibitors and flt3 inhibitors |
| JP2019512495A (en) * | 2016-03-29 | 2019-05-16 | アステラス製薬株式会社 | Combination therapy for the treatment of acute myeloid leukemia |
| CN110214138A (en) * | 2017-01-26 | 2019-09-06 | 韩美药品株式会社 | Pyrimidine compound and its medicinal usage |
-
2020
- 2020-02-21 CN CN202080015594.7A patent/CN113490497A/en active Pending
- 2020-02-21 AU AU2020226111A patent/AU2020226111A1/en active Pending
- 2020-02-21 SG SG11202108867VA patent/SG11202108867VA/en unknown
- 2020-02-21 KR KR1020200021502A patent/KR20200102949A/en unknown
- 2020-02-21 CA CA3130244A patent/CA3130244A1/en active Pending
- 2020-02-21 EP EP20759712.1A patent/EP3928780A4/en active Pending
- 2020-02-21 EA EA202191984A patent/EA202191984A1/en unknown
-
2021
- 2021-08-15 IL IL285628A patent/IL285628A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020226111A1 (en) | 2021-09-09 |
| KR20200102949A (en) | 2020-09-01 |
| EP3928780A4 (en) | 2022-12-07 |
| IL285628A (en) | 2021-09-30 |
| CN113490497A (en) | 2021-10-08 |
| EA202191984A1 (en) | 2021-11-19 |
| EP3928780A1 (en) | 2021-12-29 |
| CA3130244A1 (en) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273173A (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
| IL289366A (en) | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents | |
| IL285628A (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| SG11202011886TA (en) | PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF | |
| IL284015A (en) | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia | |
| IL284663A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| EP3858353A4 (en) | Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof | |
| ZA202204657B (en) | Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia | |
| IL286872A (en) | Antisense oligonucleotides for the treatment of usher syndrome | |
| EP3708173C0 (en) | Pharmaceutical composition comprising mirna-3140 for use in treating cancer | |
| MX2021010115A (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia. | |
| EP3821886A4 (en) | Pharmaceutical composition for preventing or treating cancer, comprising gossypol, phenformin, and anticancer agent | |
| IL268224A (en) | Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients | |
| EP3615020A4 (en) | Methods, agents, and compositions for the treatment of acute myeloid leukemia | |
| EP3804722A4 (en) | Treatment agent and pharmaceutical composition for glioma | |
| GB2589635B (en) | Elongate form medicament carrier and medicament dispenser | |
| EP3826634A4 (en) | Ire1 alpha inhibitor in combination with cancer therapeutic agent for cancer treatment | |
| PL3897758T3 (en) | Agent for treating bleeding wounds | |
| SG11202108656UA (en) | Pharmaceutical composition for preventing in-stent restenosis | |
| EP3773582C0 (en) | Selective anti-cancer agent effective for prevention and treatment | |
| EP3886833A4 (en) | Therapeutic methods and compositions for treating acute myeloid leukemia using devimistat | |
| KR102349013B9 (en) | Composition for preventing and treating a cancer comprising melatonin | |
| ZA202201449B (en) | Veterinary compositions for the prevention and/or treatment of cryptosporidiosis | |
| GB202008288D0 (en) | Methods and compositions for treating and combatting sars-cov and sars-cov-2 | |
| GB202005987D0 (en) | Methods and compositions for treating and combatting sars-cov and sars-cov-2 |